Join fellow oncology professionals at the 2023 ASCO Annual Meeting – a unique and unparalleled opportunity to connect with one of the largest, most diverse audiences in global cancer care
Congress
American Society of Clinical Oncology (ASCO) Congress 2023
American Society of Clinical Oncology (ASCO) Congress from 2nd - 6th of June 2023, Chicago, USA
-
Event type:Congress
-
Date2 Jun 2023 - 6 Jun 2023
-
Location
Join more than 40,000 oncology professionals from around the world at the 2023 ASCO Annual Meeting. Stay up to date on new clinical cancer advances in every area of cancer research, gain real-time insights from world-renowned faculty, and connect with one of the largest, most diverse audiences in global oncology—in person or online.
Why You Should Attend
- Cutting-edge research: more than 2,500 abstract presentations
- Personal stories: a diverse lineup of ASCO Voices that will showcase a variety of personal narratives and perspectives from the oncology community that illustrate the compassionate side of cancer care
- Practice-changing science: state-of-the-art tools, standards, and models for quality care
- Professional development: career resources and mentorship opportunities
- Oncology community: in-person relationship-building opportunities and online discussions with thought leaders, industry experts, and peers
- Versatile, interactive experience: livestreaming of oral abstract sessions, poster walks, Q&A, exhibits, and more
- Take-home resources: meeting materials, downloadable slides, and continuing education
More content available within our dedicated Learning Zones and Speciality Hubs
Oncology
A detailed look at conditions connected to Oncology.
Genitourinary Cancer
Containing relevant Learning Zones, guidelines, trials and news.
Supportive care in oncology Learning Zone
Supportive care in oncology from a multidisciplinary team involves caring for patients with cancer, treatment adherence and adverse effect management.
CDK4/6 inhibitors in breast cancer
Are you familiar with the clinical trial evidence that could help you to select the best cyclin dependent kinase 4/6 (CDK4/6) inhibitor for your metastatic breast cancer patient?
Molecular diagnostics for RET inhibition in NSCLC and thyroid cancers
Discover assorted resources and expert opinions on molecular diagnostics for RET inhibition in non-small cell lung cancer (NSCLC) and thyroid cancers.